As July concludes, momentum in lung cancer research continues to build, marked by FDA decisions, trial progress, and ...

Jaypirca led to better response rates than Imbruvica in some previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

As July concludes, the landscape of hematologic oncology continues to evolve, with notable progress in multiple myeloma, ...

The FDA awarded orphan drug designation to VT3989 for mesothelioma, supporting the experimental cancer treatment’s ...

Clinical trials should be designed to ease travel and financial burdens by using local care, telehealth and remote tools, ...

Navigating a metastatic castration-resistant prostate cancer (mCRPC) diagnosis while preserving self-identity can feel like ...